Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate anecortave acetate compared to placebo for
maintenance of visual acuity after 24 months of treatment in patients with subfovial
choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD).